Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3450-3461

  Kron, Ken ^a,b   Trudel, Dominique ^c   Pethe, Vaijayanti ^a   Briollais, Laurent ^a   Fleshner, Neil ^c   Van Der Kwast, Theodorus ^b,c   Bapat, Bharati ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PROSTATE SPECIFIC ANTIGEN; ERG PROTEIN, HUMAN; POLYCOMB GROUP PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DNA DETERMINATION; DNA METHYLATION; EPIGENETICS; ERG ONCOGENE; GENE LOCUS; GENETIC ASSOCIATION; GLEASON SCORE; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; CANCER GRADING; CLUSTER ANALYSIS; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PROSTATE TUMOR;

CLUSTER ANALYSIS; DISEASE PROGRESSION; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; HUMANS; MALE; MOLECULAR SEQUENCE ANNOTATION; NEOPLASM GRADING; POLYCOMB-GROUP PROTEINS; PROSTATIC NEOPLASMS; TRANS-ACTIVATORS;

EID: 84879878156     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3139     Document Type: Article

References (49)

1. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
3. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
4. Shariat SF, Scherr DS, Gupta A, Bianco FJ Jr, Karakiewicz PI, Zeltser IS, et al. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol 2011;64:681-94.
5. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
6. Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R. Current practice of Gleason grading of prostate carcinoma. Virchows Arch 2006;448:111-8. (Pubitemid 43237875)
7. Chen JL, Li J, Kiriluk KJ, Rosen AM, Paner GP, Antic T, et al. Deregulation of a hox protein regulatory network spanning prostate cancer initiation and progression. Clin Cancer Res 2012;18:4291-302.
8. Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol 2012;25:1543-9.
9. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8. (Pubitemid 41528150)
10. Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 2011;25:471-9.
11. Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q, et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010;23:1325-33.
12. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009;41:524-6.
13. Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS ONE 2011;6:e21650.
14. Markert EK, Mizuno H, Vazquez A, Levine AJ. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A 2011;108:21276-81.
15. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514-9. (Pubitemid 34193971)
16. Kim H, Lapointe J, Kaygusuz G, Ong DE, Li C, van de Rijn M, et al. The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res 2005;65:8118-24. (Pubitemid 41330574)
17. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, et al. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 2011;21:1017-27.
18. Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, et al. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 2012;18:2882-95.
19. Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X, et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A 2008;105:12979-84.
20. Avissar-Whiting M, Koestler DC, Houseman EA, Christensen BC, Kelsey KT, Marsit CJ. Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma. Epigenetics 2011;6:703-9.
21. Chen YL, Ko CJ, Lin PY, Chuang WL, Hsu CC, Chu PY, et al. Clustered DNAmethylation changes in polycomb target genes in early-stage liver cancer. Biochem Biophys Res Commun 2012;425:290-6.
22. Sun C, Dobi A, Mohamed A, Li H, ThangapazhamRL, Furusato B, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008;27:5348-53.
23. Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, et al. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res 2012;18:2896-904.
24. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, et al. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS ONE 2009;4:e4830.
25. Demetrashvili N, Kron K, Pethe V, Bapat B, Briollais L. How to deal with batch effect in sequential microarray experiments? Mol Inf 2010;29:7.
26. Ji H, Jiang H, Ma W, Johnson DS, Myers RM, Wong WH. An integrated software system for analyzing ChIP-chip and ChIP-seq data. Nat Biotechnol 2008;26:1293-300.
27. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
28. Takeshima H, Yamashita S, Shimazu T, Niwa T, Ushijima T. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res 2009;19:1974-82.
29. Kron KJ, Liu L, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, et al. DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest 2010;90:1060-7.
30. Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. BiochemBiophys ResCommun 2001;287:705-13. (Pubitemid 32912772)
31. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17:443-54.
32. Holm K, Grabau D, Lovgren K, Aradottir S, Gruvberger-Saal S, Howlin J, et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol 2012;6:494-506.
33. Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, et al. Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 2011;129:2454-62.
34. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-9. (Pubitemid 47206938)
35. Brase JC, Johannes M, Mannsperger H, Falth M, Metzger J, Kacprzyk LA, et al. TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 2011;11:507.
36. Rickman DS, Soong TD, Moss B, Mosquera JM, Dlabal J, Terry S, et al. Oncogene-mediated alterations in chromatin conformation. Proc Natl Acad Sci U S A 2012;109:9083-8.
37. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1and epigenetic reprogramming. Cancer Res 2006;66:10242-6. (Pubitemid 44799738)
38. Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, et al. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS ONE 2010;5:e10547.
39. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871-4. (Pubitemid 43255707)
40. Vinarskaja A, Schulz WA, Ingenwerth M, Hader C, Arsov C. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. Urol Oncol. 2011 Jul 29. [Epub ahead of pront].
41. Kim JH, DhanasekaranSM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 2011;21:1028-41.
42. Borno ST, Fischer A, Kerick M, Falth M, Laible M, Brase JC, et al. Genome-wide DNA methylation events in TMPRSS2:ERG fusion negative prostate cancers implicate an EZH2 dependent mechanism with miRNA-26a hypermethylation. Cancer Discov 2012;2:1024-35.
43. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, et al. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A 2007;104:5527-32. (Pubitemid 47175714)
44. Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res 2009;11:R14.
45. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, et al. CpG island hypermethylation in human astrocytomas. Cancer Res 2010;70:2718-27.
46. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-6. (Pubitemid 46184355)
47. Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R, et al. The emerging role of histone lysine demethylases in prostate cancer. Mol Cancer 2012;11:52.
48. Bhutani N, Burns DM, Blau HM. DNA demethylation dynamics. Cell 2011;146:866-72.
49. Niehrs C, Schafer A. Active DNA demethylation by Gadd45 and DNA repair. Trends Cell Biol 2012;22:220-7.